Market Cap 10.67B
Revenue (ttm) 10.90M
Net Income (ttm) -322.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,956.88%
Debt to Equity Ratio 0.00
Volume 2,394,900
Avg Vol 5,922,226
Day's Range N/A - N/A
Shares Out 150.68M
Stochastic %K 80%
Beta 0.97
Analysts Sell
Price Target $72.21

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 401 7900
Address:
10578 Science Center Drive, Suite 125, San Diego, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:24 AM
$RNA: The last close at $70.8 indicates a strong upward movement, with the RSI at 72.47 suggesting overbought conditions. This could lead to a potential pullback. The MA30 at 59.33 and MA50 at 52.87 confirm a bullish trend, but the high of $71.09 within the last 60 days indicates resistance. Directional bias is cautiously bearish in the short term due to the high RSI, which typically signals a correction. Suggested entry could be around $69.50 if a pullback occurs. Set a stop loss at $68.00 to manage risk. Targets can be set at $72.00, just above the 60D high, and $74.00, allowing for potential continuation if momentum resumes. Monitor closely for any signs of trend reversal or further strength. https://privateprofiteers.com
0 · Reply
StreetwiseReports
StreetwiseReports Nov. 14 at 6:08 PM
US$12 Billion RNA Deal Triggers Sector Shakeup https://ow.ly/couI50XrSPW Avidity Biosciences Inc. ($RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
0 · Reply
dgbio
dgbio Nov. 14 at 6:06 PM
$RNA Gloves are off in biotech. First it was Novo vs Pfizer, now Lundbeck is trying to overbid Alkermes on Avadel. Why not another bid for Avidity? Even at 100 per share it's a good deal for a buyer.
0 · Reply
wwmeinc
wwmeinc Nov. 14 at 5:21 PM
$RNA ...Quite the slow but upwards crawl to that $72 cash....but with the SpinCo trade still to play out....What if the mgmt(RNA) receives an offer today for the planned assets(SpinCo)....Would they not automatically give shareholders those newly minted funds....by either adding them to the $72 cash...or a special cash dividend? A few possibilities here...and they are all great! Just some thoughts...glta.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:57 AM
$RNA trade plan: Market context shows $RNA closing at $70.84, near its 60D high of $70.98, indicating strong upward momentum. The RSI at 98.01 suggests it is overbought, which may lead to a price correction. The MA30 at 58.54 and MA50 at 52.46 are significantly lower than the current price, indicating a potential divergence and a lack of support at these moving averages. Directional bias is bearish in the short term due to the overbought RSI and proximity to the 60D high. Suggested entry: Consider entering a short position around $70.50. Stop: Place a stop loss at $71.50 to mitigate risk. Targets: First target at $65.00, aligning with potential support levels, and a second target at $60.00, near the MA30. Monitor for any changes in momentum or market sentiment that could affect this plan. https://privateprofiteers.com
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 13 at 3:38 PM
$KURA $RNA $SNDX zifto approved EARLY! https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-kura-oncologys-blood-cancer-therapy-2025-11-13/
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:04 AM
$RNA: The stock closed at $70.7, just below the 60-day high of $70.76, indicating strong recent momentum. The RSI at 98.18 suggests that the stock is in overbought territory, which could lead to a pullback. The 30-day moving average (MA30) at 56.72 and the 50-day moving average (MA50) at 51.55 indicate a bullish trend, but the significant distance from these averages raises caution. Directional bias is bullish based on the recent price action, but the high RSI signals potential reversal risks. Suggested entry: If the price retraces to around $68.50, providing a better risk-reward setup. Stop: Set at $66 to manage downside risk. Targets: First target at $72, aligning with the recent high, and a second target at $75, considering potential bullish continuation if momentum persists. https://privateprofiteers.com
1 · Reply
Paulseekerkey
Paulseekerkey Nov. 12 at 2:11 PM
Maybe they will deliver on what they promised because they are following the books and growing the buissness that is morally good let’s see what direction they’ve taken the actual growth of the empire of government
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:40 AM
$RNA: The stock closed at $70.7, just below the 60-day high of $70.76, indicating strong recent momentum. The RSI at 98.18 suggests that the stock is in overbought territory, which could lead to a pullback. The 30-day moving average (MA30) at 56.72 and the 50-day moving average (MA50) at 51.55 indicate a bullish trend, but the significant distance from these averages raises caution. Directional bias is bullish based on the recent price action, but the high RSI signals potential reversal risks. Suggested entry: If the price retraces to around $68.50, providing a better risk-reward setup. Stop: Set at $66 to manage downside risk. Targets: First target at $72, aligning with the recent high, and a second target at $75, considering potential bullish continuation if momentum persists. https://privateprofiteers.com
0 · Reply
wwmeinc
wwmeinc Nov. 11 at 10:11 PM
$RNA CNBC's Fast Money segment tonight had a list of very large pharma deals.....Hmmm....they forgot about our $12B cash deal....No matter..."those who know, knows RNA" ;)...Nice little kicker in-coming from that SpinCo...AOC Platform et al...Patiently waiting for the date of record...glta "Avidity is working with Bristol Myers Squibb to develop therapies for up to five cardiovascular targets. The company's early-stage cardiology programs, along with its muscle and immunology programs, will be part of a new company called SpinCo, following its acquisition by Novartis. Research advancements: Preclinical studies have shown that the AOC platform can significantly increase the delivery of RNA to skeletal muscle, with sustained inhibition over time."
0 · Reply
Latest News on RNA
3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 17 days ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP


Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 10:22 AM EDT - 18 days ago

Is it too late to buy Avidity stock after Novartis deal?


Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 18 days ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS


Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 19 days ago

Novartis to acquire Avidity Biosciences for about $12B

NVS


Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 19 days ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS


Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 19 days ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:24 AM
$RNA: The last close at $70.8 indicates a strong upward movement, with the RSI at 72.47 suggesting overbought conditions. This could lead to a potential pullback. The MA30 at 59.33 and MA50 at 52.87 confirm a bullish trend, but the high of $71.09 within the last 60 days indicates resistance. Directional bias is cautiously bearish in the short term due to the high RSI, which typically signals a correction. Suggested entry could be around $69.50 if a pullback occurs. Set a stop loss at $68.00 to manage risk. Targets can be set at $72.00, just above the 60D high, and $74.00, allowing for potential continuation if momentum resumes. Monitor closely for any signs of trend reversal or further strength. https://privateprofiteers.com
0 · Reply
StreetwiseReports
StreetwiseReports Nov. 14 at 6:08 PM
US$12 Billion RNA Deal Triggers Sector Shakeup https://ow.ly/couI50XrSPW Avidity Biosciences Inc. ($RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
0 · Reply
dgbio
dgbio Nov. 14 at 6:06 PM
$RNA Gloves are off in biotech. First it was Novo vs Pfizer, now Lundbeck is trying to overbid Alkermes on Avadel. Why not another bid for Avidity? Even at 100 per share it's a good deal for a buyer.
0 · Reply
wwmeinc
wwmeinc Nov. 14 at 5:21 PM
$RNA ...Quite the slow but upwards crawl to that $72 cash....but with the SpinCo trade still to play out....What if the mgmt(RNA) receives an offer today for the planned assets(SpinCo)....Would they not automatically give shareholders those newly minted funds....by either adding them to the $72 cash...or a special cash dividend? A few possibilities here...and they are all great! Just some thoughts...glta.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:57 AM
$RNA trade plan: Market context shows $RNA closing at $70.84, near its 60D high of $70.98, indicating strong upward momentum. The RSI at 98.01 suggests it is overbought, which may lead to a price correction. The MA30 at 58.54 and MA50 at 52.46 are significantly lower than the current price, indicating a potential divergence and a lack of support at these moving averages. Directional bias is bearish in the short term due to the overbought RSI and proximity to the 60D high. Suggested entry: Consider entering a short position around $70.50. Stop: Place a stop loss at $71.50 to mitigate risk. Targets: First target at $65.00, aligning with potential support levels, and a second target at $60.00, near the MA30. Monitor for any changes in momentum or market sentiment that could affect this plan. https://privateprofiteers.com
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 13 at 3:38 PM
$KURA $RNA $SNDX zifto approved EARLY! https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-kura-oncologys-blood-cancer-therapy-2025-11-13/
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:04 AM
$RNA: The stock closed at $70.7, just below the 60-day high of $70.76, indicating strong recent momentum. The RSI at 98.18 suggests that the stock is in overbought territory, which could lead to a pullback. The 30-day moving average (MA30) at 56.72 and the 50-day moving average (MA50) at 51.55 indicate a bullish trend, but the significant distance from these averages raises caution. Directional bias is bullish based on the recent price action, but the high RSI signals potential reversal risks. Suggested entry: If the price retraces to around $68.50, providing a better risk-reward setup. Stop: Set at $66 to manage downside risk. Targets: First target at $72, aligning with the recent high, and a second target at $75, considering potential bullish continuation if momentum persists. https://privateprofiteers.com
1 · Reply
Paulseekerkey
Paulseekerkey Nov. 12 at 2:11 PM
Maybe they will deliver on what they promised because they are following the books and growing the buissness that is morally good let’s see what direction they’ve taken the actual growth of the empire of government
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:40 AM
$RNA: The stock closed at $70.7, just below the 60-day high of $70.76, indicating strong recent momentum. The RSI at 98.18 suggests that the stock is in overbought territory, which could lead to a pullback. The 30-day moving average (MA30) at 56.72 and the 50-day moving average (MA50) at 51.55 indicate a bullish trend, but the significant distance from these averages raises caution. Directional bias is bullish based on the recent price action, but the high RSI signals potential reversal risks. Suggested entry: If the price retraces to around $68.50, providing a better risk-reward setup. Stop: Set at $66 to manage downside risk. Targets: First target at $72, aligning with the recent high, and a second target at $75, considering potential bullish continuation if momentum persists. https://privateprofiteers.com
0 · Reply
wwmeinc
wwmeinc Nov. 11 at 10:11 PM
$RNA CNBC's Fast Money segment tonight had a list of very large pharma deals.....Hmmm....they forgot about our $12B cash deal....No matter..."those who know, knows RNA" ;)...Nice little kicker in-coming from that SpinCo...AOC Platform et al...Patiently waiting for the date of record...glta "Avidity is working with Bristol Myers Squibb to develop therapies for up to five cardiovascular targets. The company's early-stage cardiology programs, along with its muscle and immunology programs, will be part of a new company called SpinCo, following its acquisition by Novartis. Research advancements: Preclinical studies have shown that the AOC platform can significantly increase the delivery of RNA to skeletal muscle, with sustained inhibition over time."
0 · Reply
Paulseekerkey
Paulseekerkey Nov. 11 at 3:23 PM
$RNA in 10 years this will actually be a profitable company seems like a solid pitch
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 12:59 PM
Chardan Capital has adjusted their stance on Avidity Biosciences ( $RNA ), setting the rating to Neutral with a target price of 72.
0 · Reply
dgbio
dgbio Nov. 11 at 7:03 AM
$RNA 10m milestone from Lilly and 2.5m collaboration revenue from BMS in Q3. Both agreements are outside of the buyout and belong to SpinCo. Both are active ongoing projects. Meanwile, market appears to value SpinCo at zero. This should change.
1 · Reply
DonCorleone77
DonCorleone77 Nov. 10 at 9:13 PM
$RNA Avidity Biosciences reports Q3 EPS ($1.27), consensus ($1.10) -- Q3 revenue $12.5M, consensus $1.81M.
0 · Reply
wwmeinc
wwmeinc Nov. 7 at 2:07 PM
$RNA $NVS Just waiting patiently as a RNA shareholder...deal as it looks very fair...Spinco is going to be a winner,eventually though...as talent married w/science is key...just some thoughts...glta "Terms of the agreement Price: Novartis will acquire all outstanding shares of Avidity for $72.00 per share. Timeline: The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval and the separation of Avidity's cardiology assets. Avidity spin-off: As part of the deal, Avidity's early-stage precision cardiology programs will be spun off into a new, publicly traded company known as "SpinCo". Avidity shareholders will receive one share of SpinCo for every ten shares of Avidity they own."
0 · Reply
Paulseekerkey
Paulseekerkey Nov. 6 at 5:08 PM
$RNA Believe me or not im not the only one who sees red flags and submitted complaints and reports to SEC
0 · Reply
Paulseekerkey
Paulseekerkey Nov. 6 at 4:55 PM
$RNA I hope after a few months of this stock being stuck here and the company reporting earnings losses and Upper Management suspiciously resigning and restructuring... Pump and Dumps don't happen to this type of setup because its bolstered so they can dump some everyday I promise this volume and price action is artificial. I will lmafo when the market goes down %10 which may happen soon, this stock goes nowhere I bet because its litteraly algo froze bid ask spread. So they can cash out day by day. Prediction in the next 3 weeks this stock will move 0% regardless of market crash explain to me why you disagree with that and tell me why.
0 · Reply
DonCorleone77
DonCorleone77 Nov. 6 at 12:08 PM
$RNA Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year -- Q3 revenue $452K, consensus $177.56K.
0 · Reply
tedevan
tedevan Nov. 4 at 9:31 PM
1 · Reply
Paulseekerkey
Paulseekerkey Nov. 4 at 3:21 PM
$RNA I hope they do get acquired at 72 cause it doesn't matter to me what price it trades at, "5th time I said that."
1 · Reply
Paulseekerkey
Paulseekerkey Nov. 4 at 3:19 PM
$RNA Once again I am not trading stocks on this bud nor am i picking a direction lol sad u have such poor cognitive skills to even listen or receive data lolol
0 · Reply
wwmeinc
wwmeinc Nov. 4 at 3:00 PM
$RNA ....Hmmm.....Today you are posting a "bullish" post...geez.....I believe you need a compass, as you seem to be adrift in the ocean of decisive decision-making ;))) Good trading and glta.....**On a side note while 'we' all await for this deal to pay-out...Are you following the GLP-1/GIP saga now taking place with PFE/MTSR/NVO...with VKTX sitting quietly in the wings...waiting for a suitor to come a'knocking :) "Analyst Sentiment: Some analysts view the NVS deal for RNA as a win for Avidity shareholders, with the stock price reflecting the takeover premium, and the focus is now on the deal's execution and regulatory approvals"
0 · Reply